170 related articles for article (PubMed ID: 17638733)
1. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
Suen JK; Bressler L; Shord SS; Warso M; Villano JL
Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
[TBL] [Abstract][Full Text] [Related]
9. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.
Gholam D; Chebib A; Hauteville D; Bralet MP; Jasmin C
Anticancer Drugs; 2007 Aug; 18(7):835-7. PubMed ID: 17581308
[TBL] [Abstract][Full Text] [Related]
10. [Unilateral acneiform rash in facial palsy].
Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
[TBL] [Abstract][Full Text] [Related]
11. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
12. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
Kim S; Eleff M; Nicolaou N
Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
16. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
17. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
Pryor DI; Porceddu SV; Burmeister BH; Guminski A; Thomson DB; Shepherdson K; Poulsen M
Radiother Oncol; 2009 Feb; 90(2):172-6. PubMed ID: 18976827
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
19. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Jalili A; Pinc A; Pieczkowski F; Karlhofer FM; Stingl G; Wagner SN
J Dtsch Dermatol Ges; 2008 Dec; 6(12):1066-9. PubMed ID: 19138272
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
